Celldex Therapeutics, Inc. (CLDX)
Sector: Healthcare
Industry: In Vitro & In Vivo Diagnostic Substances
Country: United States
Exchange: NASDAQ
Market cap: $3.00B
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 9, 2026
Profit #1395 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 4.3% | 4.0% | 4.7% | 5.6% |
Growth #1448 of 1484 companies
Payout #1117 of 1484 companies
Safety #710 of 1484 companies
Price #1450 of 1484 companies
